Cambridge, England – Novus Biologicals, an international supplier of antibodies, biological products and materials to various scientific sectors, have announced the opening of a new validation facility at their headquarters.
The opening of this new validation facility will help Novus to extend their validation capabilities, directly affecting their product and information distribution to the antibody market. The opening of the validation facility will prove to be very important for clients who use Novus Biologicals, as products purchased that have been vigorously tested and validated will save them time and money on their own research and experimentation.
The new facility contains a tissue culture hood, a CO2 incubator and an inverted microscope for use in Novus’s research practices. The new equipment will allow Novus to grow a range of the most common research cell lines in suspension or adherent cultures. The cell lines produced can then be used in normal applications, or can be used to perform treatments such as chemically induced hypoxia (CoCl2, DFO), or various drug treatments.
“The cells produced in this way can then be used to produce either whole cell or nuclear extracts for use in our own internal testing, or to sell as products in their own right,” commented a senior scientist at Novus. “We can also use them to perform ICC testing of our antibodies or for use in Flow cytometry. The new facility enhances our capabilities to do thorough testing and product development across the most desirable applications and species.”
To find out more about Novus Biologicals and their antibody database, visit their website at http://www.novusbio.com/ or call +44 (0)1223 426001.
